News | April 23, 2024
Devyser partners with Hamilton to automate laboratory NGS workflows
Find out more
News (3)
Devyser publishes annual report for 2023
Devyser´s annual report 2023 has today been published on the company´s website. The report is...
-2.png)
Devyser achieves breakthrough in the US with cystic fibrosis NGS test
Devyser has secured a CFTR NGS proposal with UNC Hospitals. The proposal with UNC Hospitals is...
.png)
Devyser announces study publication demonstrating dd-cfDNA detection in dual donor kidney transplant patients
Devyser Diagnostics AB announces today an article titled “Detection of donor-derived cell-free DNA...
Devyser Diagnostics AB publishes year-end report for January to December 2023
“Devyser is able to report strong sales growth and record high gross margins for the fourth...
Devyser strengthens its management team
Devyser Genomic Laboratories signs first commercial agreement
Devyser Genomic Laboratories, Devyser's US-based CLIA-certified laboratory, has signed its first...
Devyser wins tender for cystic fibrosis in Italy
Devyser has been awarded a tender for Devyser’s CFTR fragment analysis products, that are used for...
.jpg){kind=logo}
Devyser signs in vitro diagnostic agreement with Illumina to broaden access to its tests
Devyser Diagnostics AB has entered an in vitro diagnostic development agreement with Illumina, Inc....
Devyser strengthens position in Italy - wins tender for cystic fibrosis
Devyser has been awarded a tender for Devyser’s CFTR fragment analysis products, that are used for...
Devyser wins tender for non-invasive fetal RHD testing in Wales
Devyser has been awarded a tender for Devyser RHD, its product for non-invasive fetal RHD status in...
Devyser Diagnostics AB publishes quarterly report for July to September 2023
“Devyser is reporting record sales growth (+50% organic growth) for the third quarter, a further...